Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 129

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma88Dermatitis atopic88HIV infection75Rheumatoid arthritis75Systemic lupus erythematosus61Multiple sclerosis59Psoriasis53Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Type 1 diabetes mellitus38Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Cardiac amyloidosis29Sjogren's syndrome29Interstitial lung disease28Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy23Vitiligo23Hereditary angioedema22Axial spondyloarthritis21+266

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Giant cell arteritis

Not recruiting

Study on Methotrexate for Maintaining Remission in Patients with Giant Cell Arteritis After Initial Treatment with Tocilizumab and Glucocorticoids

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Methotrexate
  • Sponsor:Rheinische Friedrich-Wilhelms-Universitaet Bonn

Cardiac amyloidosis

Not recruiting

Study on the Use of Florbetaben (18F) PET Imaging for Diagnosing Cardiac AL Amyloidosis in Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:Lantheus Germany GmbH

IgA nephropathy

Not recruiting

Study on Sibeprenlimab for Patients with IgA Nephropathy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sibeprenlimab
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Asthma

Not recruiting

Study on Asthma Control and Adherence with Mepolizumab in Pre-filled Devices for Patients with Asthma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Hospices Civils De Lyon

Rheumatoid arthritis

Not recruiting

Study on Thiamine for Reducing Fatigue in Rheumatoid Arthritis Patients

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Benfotiamine
  • Sponsor:Region Midtjylland

Crohn's disease

Not recruiting

Study on the Safety and Effects of MBF-118 for Crohn's Disease Patients with Stenosis

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Mbf-118
  • Sponsor:Medibiofarma S.L.

Axial spondyloarthritis+1

Not recruiting

Study on Upadacitinib for Adults with Active Axial Spondyloarthritis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abt-494
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Dermatitis atopic+1

Not recruiting

Study on the Effect of a New Moisturiser with Paraffin and Liquid Paraffin on Preventing Eczema Relapse in Children

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Glycerol
  • Sponsor:Aco Hud Nordic AB

Cholangitis sclerosing

Not recruiting

Study on the Safety and Tolerability of A3907 for Adults with Primary Sclerosing Cholangitis (PSC)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:A3907
  • Sponsor:Albireo AB

Type 1 diabetes mellitus

Not recruiting

Study on Colchicine for Reducing Inflammation in Patients with Type 1 Diabetes

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Gentofte Hospital

Autoimmune haemolytic anaemia+1

Not recruiting

Study for Patients with Advanced Malignancies: Continued Treatment with Parsaclisib Alone or with Itacitinib, Ruxolitinib, Ibrutinib, or Tafasitamab

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Incyte Corp.

Dermatitis atopic

Not recruiting

Study on Dupilumab Step-Down Strategy for Maintaining Remission in Adults and Adolescents with Atopic Dermatitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Clobetasol
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine39 clinical trialsTocilizumab38 clinical trialsTenofovir Alafenamide37 clinical trialsMethotrexate36 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.